BioAtla, Inc.

NasdaqGM:BCAB Stock Report

Market Cap: US$30.9m

BioAtla Future Growth

Future criteria checks 2/6

BioAtla's earnings are forecast to decline at 8.2% per annum while its annual revenue is expected to grow at 43.9% per year. EPS is expected to grow by 11.5% per annum.

Key information

-8.2%

Earnings growth rate

11.5%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate43.9%
Future return on equityn/a
Analyst coverage

Low

Last updated06 Dec 2024

Recent future growth updates

Recent updates

BioAtla's FDA Fast-Tracked Drug Candidate Boosts Its Oncology Prospects, Speculative Buy

Oct 08

We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate

Jul 16
We're A Little Worried About BioAtla's (NASDAQ:BCAB) Cash Burn Rate

BioAtla: A Buried ADC Concern Gets Some New Life In 2024

May 02

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Mar 14
Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?

Nov 05
Is BioAtla (NASDAQ:BCAB) In A Good Position To Deliver On Growth Plans?

We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully

Jun 27
We Think BioAtla (NASDAQ:BCAB) Needs To Drive Business Growth Carefully

Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

Mar 24
Will BioAtla (NASDAQ:BCAB) Spend Its Cash Wisely?

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

Sep 27
BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

BioAtla: Back From The Dead

Sep 23

BioAtla: Promising Signal In NSCLC, But Concerns Remain

Aug 23

BioAtla reports Q2 results

Aug 09

We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate

May 11
We're Keeping An Eye On BioAtla's (NASDAQ:BCAB) Cash Burn Rate

Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth

Jan 06
Companies Like BioAtla (NASDAQ:BCAB) Are In A Position To Invest In Growth

BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

Jul 24
BioAtla (NASDAQ:BCAB) Is In A Good Position To Deliver On Growth Plans

Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?

Mar 16
Are Insiders Buying BioAtla, Inc. (NASDAQ:BCAB) Stock?

Earnings and Revenue Growth Forecasts

NasdaqGM:BCAB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026N/A-108N/AN/A3
12/31/2025N/A-92N/AN/A3
12/31/202411-75N/AN/A3
9/30/202411-82-85-85N/A
6/30/2024N/A-105-107-107N/A
3/31/2024N/A-119-112-112N/A
12/31/2023N/A-123-104-104N/A
9/30/2023N/A-124-99-98N/A
6/30/2023N/A-117-95-95N/A
3/31/2023N/A-110-88-88N/A
12/31/2022N/A-106-91-90N/A
9/30/2022N/A-102-87-87N/A
6/30/2022N/A-99-76-76N/A
3/31/20220-101-73-72N/A
12/31/20210-95-63-62N/A
9/30/20210-79-57-55N/A
6/30/20210-68-59-58N/A
3/31/20210-44-49-48N/A
12/31/20200-27-37-36N/A
9/30/20203-22-25-24N/A
12/31/20195-29-11-10N/A
12/31/201811-28-36-35N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BCAB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BCAB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BCAB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BCAB's revenue (43.9% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: BCAB's revenue (43.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BCAB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 01:47
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BioAtla, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Justin ZelinBTIG
Tiago FauthCredit Suisse